Anti-Programmed Cell Death (PD) Therapies for the Management of Patients with Lung Cancer

Program Dates: February 8th, 2021 - February 7th, 2022
Credits: 0.75 AMA PRA Category 1 Credits™

Anti-Programmed Cell Death (PD) Therapies for the Management of Patients with Lung Cancer

Program Overview

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and M. Patricia Rivera, will first provide a review of current science in non-small cell lung cancer (NSCLC), including trends in stage distribution of lung cancer. Following, current data for targeted therapies as well as immunotherapies in various NSCLC patient populations will be analyzed and clinical implications debated. Strategies for utilizing evidence-based medicine strategies to create personalized treatment plans will also be highlighted. This program will update clinicians on current practices to improve clinical outcomes and quality of life for patients with non-small cell lung cancer.

Target Audience

Pulmonologists, primary care physicians, PAs, NPs, nurses, pharmacists, and other healthcare professionals involved in the management of patients with NSCLC

Learning Objectives

  1. Review the science of anti-PD-1 and PD-L1-based therapeutic targets in patients with NSCLC
  2. Examine the current clinical trial data for anti-PD agents to improve outcomes in patients with NSCLC
  3. Implement evidence-based medicine strategies, including anti-PD-1 therapeutics, into treatment plans for the effective care of patients with NSCLC


  1. Review the Science of Anti-PD-1 and PD-L1-based Therapeutic Targets in Patients with NSCLC
  2. Clinical Trial Data Review of Anti-PD-1 and PD-L1 Agents to Improve Patient Outcomes
  3. Evidence-based Therapeutic Strategies for Managing Patients with NSCLC


Sidney S. Braman, MD
Professor of Medicine
Pulmonary, Critical Care and Sleep Medicine
Icahn School of Medicine at Mount Sinai
New York, New York



Patricia Rivera, MD
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Co-Director Multidisciplinary Thoracic Oncology Program
Director, Lung Cancer Screening Program
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Sidney S. Braman, MD


Consultant/Advisor: Sunovion Pharmaceuticals Inc.

Speakers Bureau: AstraZeneca Pharmaceuticals; Boehringer Ingelheim; GmbH, Inc; Genentech, Inc.

M. Patricia Rivera, MD


Consultant/Advisor: bioAffinity Technologies, Inc.; Biodesix; Johnson & Johnson Services, Inc.

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Credit Designation Statements

AcademicCME designates this live material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by independent educational grants from AstraZeneca Pharmaceuticals and BeiGene, LTD.

Disclosure of Unlabeled Use

is educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, AstraZeneca Pharmaceuticals and BeiGene, LTD do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].



Provided by: AcademicCME-web